Breaking Finance News

Codexis Inc (NDAQ:CDXS) target price raised to $8.50, reported today by H.C. Wainwright

Yesterday Codexis Inc (NDAQ:CDXS) traded 17.16% higher at $7.65. The company’s 50-day moving average is $6.08 and its 200-day moving average is $5.18. The last stock close price is up 51.64% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 613,903 shares of the stock were exchanged, up from an average trading volume of 165,878

Codexis Inc (NDAQ:CDXS) had its target price raised to $8.50 by H.C. Wainwright in a report released 10/13/2017. The new target price indicates a possible upside of 0.11% based on the company's last stock close price.

Previously on 5/31/2017, Jefferies & Co reported about Codexis Inc (NDAQ:CDXS) raised the target price from $0.00 to $8.00. At the time, this indicated a possible upside of 1%.

See Chart Below

Codexis Inc (NDAQ:CDXS)

Codexis Inc has a 52 week low of $3.60 and a 52 week high of $7.90 The company’s market cap is currently $0.

About Codexis Inc (NDAQ:CDXS)

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.